Evaluation of polyoxyethylene homopolymers for buccal bioadhesive drug delivery device formulations.
Our objective was to evaluate the application of polyoxyethylene homopolymers in buccal bioadhesive drug (BBD) delivery device formulations. The bioadhesive strength of four different molecular weight (MW) polyoxyethylene polymers was measured by Instron tensile tester using glass plate and bovine sublingual tissue as substrate surfaces. Several BBD device formulations containing polyoxyethylene polymer (MW 7,000,000) were prepared by direct compression and compression molding processes. The prepared BBD devices were evaluated for their elasticity, in vitro adhesion and drug release characteristics. The in vivo bioadhesion characteristics of a placebo compression molded device were examined in 3 adult healthy male beagle dogs. The bioadhesive strength of polyoxyethylene polymers appeared to be directly related to their molecular weights. When bovine sublingual mucosa or a glass plate was used as model mucosal substrate surface, the rank order of bioadhesive strength of different molecular weight polyoxyethylene polymers was similar. The bioadhesive strength of devices prepared by the compression molding process was greater than those prepared by direct compression, but the kinetics of drug release were independent of the process used for the preparation of the devices. The drug release and the bioadhesive strength of the similarly prepared device formulations appeared to be dependent on the drug:polymer ratios. The elasticity of the BBD devices prepared by compression molding was improved by the inclusion of polyisobutylene polymer in the formulations. When adhered to the oral cavity of the dogs, the compression molded placebo BBD device exhibited adhesion for at least 4 hours and appeared to show no signs of local irritation. In conclusion, BBD devices containing polyoxyethylene polymer (MW 7,000,000) can be prepared by direct compression or compression molding process in order to provide controlled drug release to the oral cavity while maintaining appropriate bioadhesive characteristics.
Tiwari
D
D
College of Pharmacy & Allied Health Professions, St. John's University, Jamaica, New York 11439, USA. deepak.tiwari.b@bayer.com
Goldman
D
D
Sause
R
R
Madan
P L
PL
D000278:Administration, Buccal; D000818:Animals; D002417:Cattle; D002744:Chlorpheniramine / Q000008:administration & dosage / Q000737:chemistry; D004285:Dogs; D004337:Drug Carriers; D004339:Drug Compounding; D004548:Elasticity; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D008422:Materials Testing; D008970:Molecular Weight; D009061:Mouth Mucosa; D011092:Polyethylene Glycols / Q000737:chemistry*; D000267:Tissue Adhesions
D004337:Drug Carriers; D002744:Chlorpheniramine; D011092:Polyethylene Glycols